| Literature DB >> 35010185 |
Yujun Wan1, Xiaojuan Xu2, Robert G Gilbert1,3, Mitchell A Sullivan4.
Abstract
Type 2 diabetes, a long-term chronic metabolic disease, causes severe and increasing economic and health problems globally. There is growing evidence that β-glucans can function as bioactive macromolecules that help control type 2 diabetes with minimal side effects. However, conflicting conclusions about the antidiabetic activities of β-glucans have been published, potentially resulting from incomplete understanding of their precise structural characteristics. This review aims to increase clarity on the structure-function relationships of β-glucans in treating type 2 diabetes by examining detailed structural and conformational features of naturally derived β-glucans, as well as both chemical and instrumental methods used in their characterization, and their underlying anti-diabetic mechanisms. This may help to uncover additional structure and function relationships and to expand applications of β-glucans.Entities:
Keywords: anti-diabetic function; enzyme inhibitor; macronutrient absorption; molecular structure; type 2 diabetes; β-glucan
Year: 2021 PMID: 35010185 PMCID: PMC8750484 DOI: 10.3390/foods11010057
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Chemical structures of β-glucans. The glucose monomers are shown following the symbol nomenclature for glycans. (A) The β-1,3-linked backbone of β-glucan with different branching degree of β-1,6-linked glucose. (B) The β-1,3-1,4-linked backbone of β-glucan, DP3: cellotriosyl, DP4: cellotetraosyl).
Sources and deduced chemical structures of several β-glucans.
| Name/Abbr. | Source | Extraction Solvent | Type of Glucan | Structure a | Ref. |
|---|---|---|---|---|---|
| Curdlan | NaOH | (A) a = 1, b = 0 | [ | ||
| APP |
| NaCl | β-1,3 glucan | (A) a = 1, b = 2 | [ |
| DIP |
| Water | (A) a = 2, b = 1 | [ | |
| HEP |
| Water | (A) a = 2, b = 1 | [ | |
| GFP |
| Water | (A) a = 2, b = 1 | [ | |
| Schizophyllan |
| Water | (A) a = 2, b = 1 | [ | |
| Laminarin | Algae | Water | (A) a = 2, b = 1 | [ | |
| Lentinan |
| NaCl/NaOH | (A) a = 3, b = 2 | [ | |
| GLP |
| Water | (A) a = 5, b = 1 | [ | |
| YBG |
| NaOH | (A) a = 5, b = 1 | [ | |
| CSP | Wild | Water | (A) a = 5, b = 2 | [ | |
| WBG | Wheat | Water | (B) DP3:DP4 = 3.0–4.5 | [ | |
| BBG | Barley | Water/NaOH | (B) DP3:DP4 = 1.7–3.3 | [ | |
| RBG | Rye | Water | (B) DP3:DP4 = 1.8–3.1 | [ | |
| OBG | Oat | Water | (B) DP3:DP4 = 1.5–2.2 | [ |
a The uppercase letters within this column represent the repeating units shown in Figure 1 (A. β-1,3-1,6 glucan; B. β-1,3-1,4 glucan). The lowercase letters indicate the molar ratio of each part in the repeating units.
Figure 2Various chain conformations of polysaccharides in different solvents.
Figure 3Chemical and instrumental methods used for β-glucan structure characterization.
Drugs used in amelioration of T2D.
| Type | Drug Name | Mechanisms | Side-Effects | Ref. |
|---|---|---|---|---|
| Biguanides | Metformin, Phenformin | Lowering fasting plasma insulin concentration; enhancing insulin sensitivity; changing gut microbiota composition; promoting functional shifts in gut microbiome. | Gastrointestinal disorders; folate deficiency; increasing homocysteine levels | [ |
| Sulfonylureas | Glibenclamide, Glipizide | As insulin secretagogues to stimulate insulin secretion. | Gastrointestinal disorders, headache | [ |
| Thiazolidinediones | Rosiglitazone, Pioglitazone | Improving insulin sensitivity by up-regulation of adipokine. | Peripheral and pulmonary edema; fluid retention. | [ |
| GLP-1 | Liraglutide, Semaglutide | Suppressing glucagon release; delaying gastric emptying and increasing satiety. | Nausea, vomiting and diarrhoea | [ |
| DPP-4 inhibitors | Vidagliptin, Saxagliptin | Enhancing incretin axis; improving meal-stimulated insulin secretion by sparing incretin hormones. | Nausea and gastrointestinal problems | [ |
| SGLT2 inhibitors | Dapagliflozin, Cangliflozin | Inhibition of renal glucose reabsorption to lower plasma glucose levers. | Increasing the risk of developing diabetic ketoacidosis. | [ |
| Enzyme inhibitors | α-amylase inhibitors, α-glucosidase inhibitors, | Reduction in the rate of glucose absorption in post-prandial blood | Lactic acidosis, diarrhoea, liver function disorders. | [ |
Figure 4The proposed mechanism of enzyme inhibition. (A) The normal enzyme–substrate interactions during digestion. (B) β-glucans play as a physical barrier to inhibit enzyme–substrate interactions. (C) β-glucans bind to enzymes to inhibit enzyme–substrate interactions.